SCHEMBL13041323

SCHEMBL13041323

Cn1c(=O)c(-c2nc3ccccc3n2S(=O)(=O)C(F)(F)F)c(OS(=O)(=O)C(F)(F)F)c2ccccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.36
PDGFRB P09619 2/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 4/20 0.36
GAA P10253 3/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
LMNA P02545 3/20 0.36
KMT2A Q03164 2/20 0.36
HIF1A Q16665 1/20 0.35
ALDH3A1 P30838 1/20 0.34
FGFR1 P11362 1/20 0.34
MAPT P10636 2/20 0.34
AURKA O14965 1/20 0.34
AURKB Q96GD4 1/20 0.34
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041320 0.85 PDGFRB (0.40) KDRPDGFRBALDH1A1KDM4EGAA
SCHEMBL13041384 0.75 TP53 (0.45) ALDH1A1KDM4EGAAHPGDSMN1; SMN2
SCHEMBL25074982 0.71 EGFR (0.44) ALDH1A1KDM4EGAAHPGDSMN1; SMN2
SCHEMBL30249078 0.71 EGFR (0.44) ALDH1A1KDM4EGAAHPGDSMN1; SMN2
SCHEMBL26906474 0.68 SMN1; SMN2 (0.44) ALDH1A1KDM4EGAAHPGDSMN1; SMN2
SCHEMBL7897644 0.63 ALDH1A1 (0.43) ALDH1A1KDM4EGAAHPGDSMN1; SMN2
SCHEMBL7531474 0.61 L3MBTL1 (0.50) ALDH1A1KDM4EGAASMN1; SMN2LMNA
SCHEMBL28634325 0.61 KDM4E (0.55) KDRPDGFRBALDH1A1KDM4EGAA
SCHEMBL29559577 0.61 KDM4E (0.55) KDRPDGFRBALDH1A1KDM4EGAA
SCHEMBL23293473 0.61 PDE4A (0.36) ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825132-B2 Inhibition of FGFR3 and treatment of multiple myeloma NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-11-02 US disclosed
US-20090281100-A1 Benzimidazole quinolinones and uses thereof BARSANTI PAUL A 2009-11-12 US disclosed
US-7470709-B2 Benzimidazole quinolinones and uses thereof NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281100-A1 Benzimidazole quinolinones and uses thereof GAA, ALPI, IL4I1 KDR 4671/4885PDGFRB 3508/4885ALDH1A1 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.